These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury. Simpson PJ; Schelm JA; Smallwood JK; Clay MP; Lindstrom TD J Cardiovasc Pharmacol; 1992 Jun; 19(6):987-95. PubMed ID: 1376823 [TBL] [Abstract][Full Text] [Related]
33. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. Forman MB; Pitarys CJ; Vildibill HD; Lambert TL; Ingram DA; Virmani R; Murray JJ J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335 [TBL] [Abstract][Full Text] [Related]
34. The preischemic combination of the sodium-hydrogen exchanger inhibitor cariporide and the adenosine agonist AMP579 acts additively to reduce porcine myocardial infarct size. Kristo G; Yoshimura Y; Ferraris SP; Jahania SA; Mentzer RM; Lasley RD J Am Coll Surg; 2004 Oct; 199(4):586-94. PubMed ID: 15454144 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. McVey MJ; Smits GJ; Cox BF; Kitzen JM; Clark KL; Perrone MH J Cardiovasc Pharmacol; 1999 May; 33(5):703-10. PubMed ID: 10226856 [TBL] [Abstract][Full Text] [Related]
36. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Blease K; Burke-Gaffney A; Hellewell PG Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364 [TBL] [Abstract][Full Text] [Related]
37. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury. Souza DG; Cassali GD; Poole S; Teixeira MM Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446 [TBL] [Abstract][Full Text] [Related]
38. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia-reperfused isolated mouse heart. Urmaliya VB; Pouton CW; Ledent C; Short JL; White PJ J Cardiovasc Pharmacol; 2010 Oct; 56(4):379-88. PubMed ID: 20930592 [TBL] [Abstract][Full Text] [Related]
39. ATL 313, A Selective A(2A) Adenosine Receptor Agonist, Reduces Myocardial Infarct Size in a Rat Ischemia/Reperfusion Model. Dai W; Hale SL; Nayak R; Kloner RA Open Cardiovasc Med J; 2009 Nov; 3():166-72. PubMed ID: 20111666 [TBL] [Abstract][Full Text] [Related]
40. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Tracey WR; Magee WP; Oleynek JJ; Hill RJ; Smith AH; Flynn DM; Knight DR Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2780-7. PubMed ID: 12919933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]